ファーマコゲノミクスにおける分子診断薬市場- 世界の産業規模、シェア、動向、機会、予測、製品別、治療分野別、地域別、競合別、2020-2030年

ファーマコゲノミクスにおける分子診断薬の世界市場規模は2024年に6億8,640万米ドル、2030年には9億6,932万米ドルに達すると予測、CAGRは6.12%。

ファーマコゲノミクスの世界分子診断市場は、個別化医療とプレシジョン・ヘルスケアの需要増加に牽引され、力強い成長を遂げています。個人の遺伝的体質が薬物反応にどのように影響するかを研究するファーマコゲノミクスは、薬物の有効性と安全性に影響する遺伝的変異を同定する分子診断技術に大きく依存しています。

分子診断薬は、ヘルスケアプロバイダーが個々の患者に合わせて薬物療法を調整することで、副作用を最小限に抑え、治療成果を最適化する上で重要な役割を果たしています。有望な市場であるにもかかわらず、規制の複雑さ、データプライバシーに関する懸念、臨床検証の強化やヘルスケア専門家の教育の必要性といった課題に直面しています。

主な市場促進要因

ヘルスケア産業の成長

主な市場課題

検査費用の高騰

主な市場動向

小児および老年人口へのフォーカス

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のファーマコゲノミクスにおける分子診断薬市場に与える影響

第5章 世界のファーマコゲノミクスにおける分子診断薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（キットおよびアッセイ、試薬、サービス、その他）
  • 治療領域別（腫瘍学、神経疾患、心血管疾患、免疫疾患、感染症、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のファーマコゲノミクスにおける分子診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のファーマコゲノミクスにおける分子診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のファーマコゲノミクスにおける分子診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のファーマコゲノミクスにおける分子診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのファーマコゲノミクスにおける分子診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界のファーマコゲノミクスにおける分子診断薬市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Roche Diagnostics
• QIAGEN
• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• Abbott Molecular
• Genomind
• OneOme
• Myriad Genetics
• Invitae

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Molecular Diagnostics In Pharmacogenomics Market was valued at USD 686.40 Million in 2024 and is expected to reach USD 969.32 Million by 2030 with a CAGR of 6.12%. The global molecular diagnostics market in pharmacogenomics is experiencing robust growth, driven by the increasing demand for personalized medicine and precision healthcare. Pharmacogenomics, which studies how an individual's genetic makeup affects their response to drugs, relies heavily on molecular diagnostic technologies to identify genetic variations that influence drug efficacy and safety.

Molecular diagnostics play a critical role in enabling healthcare providers to tailor drug therapies to individual patients, thereby minimizing adverse drug reactions and optimizing therapeutic outcomes. Despite its promising outlook, the market faces challenges such as regulatory complexities, data privacy concerns, and the need for greater clinical validation and education among healthcare professionals.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the healthcare industry is a pivotal driver fueling the expansion of the global molecular diagnostics in pharmacogenomics market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most significant and profitable segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems worldwide evolve to offer more personalized and effective treatments, there is an increasing demand for molecular diagnostic tools that enable tailored drug therapies based on an individual's genetic profile.

Hypertension and diabetes represent approximately 70% of all chronic disease cases. As India progresses through the third phase of the epidemiological transition characterized by degenerative, stress-related, and lifestyle-induced conditions the prevalence of chronic illnesses such as diabetes and cardiovascular diseases is rising significantly, driven in part by an ageing population. Rising prevalence of chronic and genetic disorders, coupled with the growing emphasis on precision medicine, is pushing healthcare providers and pharmaceutical companies to adopt pharmacogenomics-guided diagnostics. These diagnostics help optimize drug efficacy, minimize adverse drug reactions, and enhance overall patient outcomes, aligning with the healthcare industry's broader goals of improving quality of care and reducing costs.

Key Market Challenges

High Cost of Testing

The high cost of testing represents a significant challenge in the Global Molecular Diagnostics in Pharmacogenomics Market. Pharmacogenomic tests require sophisticated technology, specialized equipment, and skilled personnel, all of which contribute to substantial expenses. These elevated costs can limit the widespread adoption of pharmacogenomic testing, particularly in cost-sensitive healthcare systems and emerging markets.

Moreover, the financial burden associated with these tests often deters healthcare providers and patients from integrating pharmacogenomics into standard clinical practice. Although the promise of personalized medicine is compelling, the upfront investment needed for molecular diagnostics remains a critical barrier. Additionally, inconsistent reimbursement policies and limited insurance coverage across different regions exacerbate this challenge, leaving many patients to bear the cost out-of-pocket. This restricts access to pharmacogenomic testing and slows market growth.

Key Market Trends

Focus on Pediatric and Geriatric Populations

A significant emerging trend within the global molecular diagnostics in pharmacogenomics market is the growing focus on pediatric and geriatric populations. Currently, government policies on growth monitoring primarily target children under the age of five. Growth monitoring is a fundamental component of under-five clinics, where children are weighed regularly monthly during the first year, every two months in the second year, and quarterly thereafter up to the age of five to six years. These two demographic groups represent distinct patient segments with unique therapeutic needs and varying responses to medication, making personalized treatment approaches especially critical.

In pediatric care, molecular diagnostics enable precise identification of genetic factors that influence drug metabolism and efficacy in children. Given the physiological differences and developmental considerations in this population, pharmacogenomic testing helps clinicians optimize drug dosing and reduce the risk of adverse drug reactions, which are often more pronounced in younger patients.

Key Market Players

• Roche Diagnostics
• QIAGEN
• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• Abbott Molecular
• Genomind
• OneOme
• Myriad Genetics
• Invitae

Report Scope

In this report, the Global Molecular Diagnostics In Pharmacogenomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Diagnostics In Pharmacogenomics Market, By Product:

• Kits and Assays
• Reagents
• Services
• Others

Molecular Diagnostics In Pharmacogenomics Market, By Therapeutic Area:

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Molecular Diagnostics In Pharmacogenomics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Diagnostics In Pharmacogenomics Market.

Available Customizations:

Global Molecular Diagnostics In Pharmacogenomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Molecular Diagnostics in Pharmacogenomics Market

5. Global Molecular Diagnostics in Pharmacogenomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits and Assays, Reagents, Services, Others)
  • 5.2.2. By Therapeutic Area (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Molecular Diagnostics in Pharmacogenomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Mexico Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Canada Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Molecular Diagnostics in Pharmacogenomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. Germany Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. South Korea Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. Japan Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Therapeutic Area

9. South America Molecular Diagnostics in Pharmacogenomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. Argentina Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. Colombia Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Therapeutic Area

10. Middle East and Africa Molecular Diagnostics in Pharmacogenomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. UAE Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Molecular Diagnostics in Pharmacogenomics Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Roche Diagnostics
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. QIAGEN
• 16.3. Thermo Fisher Scientific
• 16.4. Illumina, Inc.
• 16.5. Agilent Technologies
• 16.6. Abbott Molecular
• 16.7. Genomind
• 16.8. OneOme
• 16.9. Myriad Genetics
• 16.10. Invitae

17. Strategic Recommendations

18. About Us & Disclaimer